{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:48:09Z","timestamp":1787932089068,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Maxillofac Plast Reconstr Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is one of the complications caused by various drugs. As there are increasing reports of MRONJ, it is important to diagnose and identify patients who have the potential risk of the disease. The aim of this study was to analyze the systemic diseases, etiology, and treatment results of MRONJ.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>A total of 265 MRONJ operations were reviewed retrospectively. This study included patients who were diagnosed as MRONJ and those who also received surgery, ranging from simple extraction to reconstruction with free flaps, from 2009 to 2021. Each patient\u2019s systemic disease and eitology and basic demographic information was taken into consideration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The most common diseases related were osteoporosis (<jats:italic>n<\/jats:italic> = 127), breast cancer (<jats:italic>n<\/jats:italic> = 77), multiple myeloma (<jats:italic>n<\/jats:italic> = 27), prostate cancer (<jats:italic>n<\/jats:italic> = 26), and etc. (<jats:italic>n<\/jats:italic> = 12). The related causes of MRONJ were extraction (<jats:italic>n<\/jats:italic> = 138), implants (<jats:italic>n<\/jats:italic> = 40), and irritations by prosthesis (<jats:italic>n<\/jats:italic> = 29); however, 55 cases were occurred spontaneously. Out of 265 patients, 214 were women while 51 were men. The average age when the surgery took place was 67.7 and 69.8 years for male and female patients, respectively. Saucerization and sequestrectomy (<jats:italic>n<\/jats:italic> = 252) was the most common surgical treatment, followed by mandibulectomy (<jats:italic>n<\/jats:italic> = 12) and partial maxillectomy (<jats:italic>n<\/jats:italic> = 1). While 4 cases occurred in both jaws, 168 cases were in the mandible and 93 cases were in the maxilla.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Nearly 50 % of the MRONJ patients had osteoporosis and the other patients who received bone targeting agents parentral had bone metastasis of various cancers. Extraction is the most common related event for MRONJ.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40902-023-00377-7","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:36:57Z","timestamp":1677757017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases"],"prefix":"10.1186","volume":"45","author":[{"given":"Hoon-Je","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4254","authenticated-orcid":false,"given":"Kang-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"377_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 80:920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"377_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.joms.2013.05.014","volume":"71","author":"ER Carlson","year":"2013","unstructured":"Carlson ER, Fleisher KE, Ruggiero SL (2013) Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications. J Oral Maxillofac Surg 71:2077\u20132086. https:\/\/doi.org\/10.1016\/j.joms.2013.05.014","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 2","key":"377_CR3","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","volume":"119","author":"RG Russell","year":"2007","unstructured":"Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150\u2013S162. https:\/\/doi.org\/10.1542\/peds.2006-2023H","journal-title":"Pediatrics"},{"key":"377_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66:1139\u20131146. https:\/\/doi.org\/10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"},{"key":"377_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","volume":"39","author":"P Peddi","year":"2013","unstructured":"Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39:97\u2013104. https:\/\/doi.org\/10.1016\/j.ctrv.2012.07.002","journal-title":"Cancer Treat Rev"},{"key":"377_CR6","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/eje-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"Anastasilakis AD, Polyzos SA, Makras P (2018) Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol 179:R31\u2013r45. https:\/\/doi.org\/10.1530\/eje-18-0056","journal-title":"Eur J Endocrinol"},{"key":"377_CR7","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00520-019-05044-0","volume":"28","author":"AL Soares","year":"2020","unstructured":"Soares AL, Simon S, Gebrim LH, Naz\u00e1rio ACP, Lazaretti-Castro M (2020) Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study. Support Care Cancer 28:2265\u20132271. https:\/\/doi.org\/10.1007\/s00520-019-05044-0","journal-title":"Support Care Cancer"},{"key":"377_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/adj.12648","volume":"63","author":"A Khominsky","year":"2018","unstructured":"Khominsky A, Lim M (2018) \"Spontaneous\" medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J 63:441\u2013454. https:\/\/doi.org\/10.1111\/adj.12648","journal-title":"Aust Dent J"},{"key":"377_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 24:527\u2013536. https:\/\/doi.org\/10.1111\/odi.12708","journal-title":"Oral Dis"},{"key":"377_CR10","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.oooo.2020.10.005","volume":"131","author":"L Gupta","year":"2021","unstructured":"Gupta L, Dholam K, Janghel Y, Gurav SV (2021) Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report. Oral Surg Oral Med Oral Pathol Oral Radiol 131:e157\u2013e162. https:\/\/doi.org\/10.1016\/j.oooo.2020.10.005","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"377_CR11","doi-asserted-by":"publisher","first-page":"6621937","DOI":"10.1155\/2021\/6621937","volume":"2021","author":"M Okubo-Sato","year":"2021","unstructured":"Okubo-Sato M, Yamagata K, Fukuzawa S, Terada K, Uchida F, Ishibashi-Kanno N et al (2021) Medication-related osteonecrosis of the jaw spontaneously occurred in a patient with chronic myelogenous leukemia only by imatinib: a report of a rare case. Case Rep Dent 2021:6621937. https:\/\/doi.org\/10.1155\/2021\/6621937","journal-title":"Case Rep Dent"},{"key":"377_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","volume":"43","author":"M Viviano","year":"2017","unstructured":"Viviano M, Rossi M, Cocca S (2017) A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 43:120\u2013124. https:\/\/doi.org\/10.5125\/jkaoms.2017.43.2.120","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"377_CR13","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-021-06078-z","volume":"32","author":"FL Dos Santos","year":"2021","unstructured":"Dos Santos FL, Abreu L, Calderipe C, Martins M, Schuch L, Vasconcelos A (2021) Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporosis International 32:2449\u20132459","journal-title":"Osteoporosis International"},{"key":"377_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","volume":"66","author":"F Yuan","year":"2019","unstructured":"Yuan F, Peng W, Yang C, Zheng J (2019) Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. Int J Surg 66:1\u201311. https:\/\/doi.org\/10.1016\/j.ijsu.2019.03.004","journal-title":"Int J Surg"},{"key":"377_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.oooo.2020.04.808","volume":"130","author":"F Hallmer","year":"2020","unstructured":"Hallmer F, Bjarnadottir O, G\u00f6trick B, Malmstr\u00f6m P, Andersson G (2020) Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 130:252\u2013257","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"377_CR16","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1002\/jbmr.2577","volume":"30","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Yu W, Lee S, Xu Q, Naji A, Le AD (2015) Bisphosphonate induces osteonecrosis of the jaw in diabetic mice via NLRP3\/Caspase-1-dependent IL-1\u03b2 mechanism. J Bone Min Res 30:2300\u20132312","journal-title":"J Bone Min Res"},{"key":"377_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.trsl.2021.05.001","volume":"236","author":"KI Ko","year":"2021","unstructured":"Ko KI, Sculean A, Graves DT (2021) Diabetic wound healing in soft and hard oral tissues. Transl Res 236:72\u201386","journal-title":"Transl Res"},{"key":"377_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0022034514560768","volume":"94","author":"A Peer","year":"2015","unstructured":"Peer A, Khamaisi M (2015) Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dental Res 94:252\u2013260","journal-title":"J Dental Res"},{"key":"377_CR19","doi-asserted-by":"publisher","first-page":"102460","DOI":"10.1016\/j.jaut.2020.102460","volume":"110","author":"C Chang","year":"2020","unstructured":"Chang C, Greenspan A, Gershwin ME (2020) The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun 110:102460","journal-title":"J Autoimmun"},{"key":"377_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","volume":"67","author":"ER Carlson","year":"2009","unstructured":"Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:85\u201395. https:\/\/doi.org\/10.1016\/j.joms.2009.01.006","journal-title":"J Oral Maxillofac Surg"},{"key":"377_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","volume":"47","author":"O Ristow","year":"2019","unstructured":"Ristow O, R\u00fcckschlo\u00df T, M\u00fcller M, Berger M, Kargus S, Pautke C et al (2019) Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 47:491\u2013499. https:\/\/doi.org\/10.1016\/j.jcms.2018.12.014","journal-title":"J Craniomaxillofac Surg"},{"key":"377_CR22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.joms.2008.12.057","volume":"67","author":"DC Stanton","year":"2009","unstructured":"Stanton DC, Balasanian E (2009) Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 67:943\u2013950. https:\/\/doi.org\/10.1016\/j.joms.2008.12.057","journal-title":"J Oral Maxillofac Surg"},{"key":"377_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.joms.2013.12.007","volume":"72","author":"ER Carlson","year":"2014","unstructured":"Carlson ER (2014) Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg 72:655\u2013657. https:\/\/doi.org\/10.1016\/j.joms.2013.12.007","journal-title":"J Oral Maxillofac Surg"},{"key":"377_CR24","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.joms.2020.05.037","volume":"78","author":"A Giudice","year":"2020","unstructured":"Giudice A, Barone S, Diodati F, Antonelli A, Nocini R, Cristofaro MG (2020) Can surgical management improve resolution of medication-related osteonecrosis of the jaw at early stages? A prospective cohort study. J Oral Maxillofac Surg 78:1986\u20131999. https:\/\/doi.org\/10.1016\/j.joms.2020.05.037","journal-title":"J Oral Maxillofac Surg"},{"key":"377_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10006-021-00973-9","volume":"26","author":"A Jose","year":"2022","unstructured":"Jose A, Rawat A, Nagori SA, Arya S, Shukla D (2022) Outcomes of sequestrectomy and buccal fat pad reconstruction in the management of medication-related osteonecrosis of the jaws. Oral Maxillofac Surg 26:147\u2013153. https:\/\/doi.org\/10.1007\/s10006-021-00973-9","journal-title":"Oral Maxillofac Surg"},{"key":"377_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.joms.2014.09.023","volume":"73","author":"H Rotaru","year":"2015","unstructured":"Rotaru H, Kim MK, Kim SG, Park YW (2015) Pedicled buccal fat pad flap as a reliable surgical strategy for the treatment of medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 73:437\u2013442. https:\/\/doi.org\/10.1016\/j.joms.2014.09.023","journal-title":"J Oral Maxillofac Surg"},{"key":"377_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","volume":"27","author":"T Aghaloo","year":"2015","unstructured":"Aghaloo T, Hazboun R, Tetradis S (2015) Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 27:489\u2013496. https:\/\/doi.org\/10.1016\/j.coms.2015.06.001","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"377_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-824x-5-1","volume":"5","author":"D Sharma","year":"2013","unstructured":"Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K et al (2013) Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 5:1. https:\/\/doi.org\/10.1186\/2045-824x-5-1","journal-title":"Vasc Cell"},{"key":"377_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10006-020-00927-7","volume":"25","author":"S Moll","year":"2021","unstructured":"Moll S, Mueller S, Meier JK, Reichert TE, Ettl T, Klingelh\u00f6ffer C (2021) Patients\u2019 quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw. Oral Maxillofac Surg 25:359\u2013366. https:\/\/doi.org\/10.1007\/s10006-020-00927-7","journal-title":"Oral Maxillofac Surg"}],"container-title":["Maxillofacial Plastic and Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40902-023-00377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40902-023-00377-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40902-023-00377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:37:00Z","timestamp":1677757020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jkamprs.springeropen.com\/articles\/10.1186\/s40902-023-00377-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/s40902-023-00377-7","relation":{},"ISSN":["2288-8586"],"issn-type":[{"value":"2288-8586","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"24 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}